CICC: Maintaining Federal Pharmaceuticals (03933.HK)'s “outperforming the industry” rating target price of HK$10.5
Federal Pharmaceuticals (03933.HK): Group A won the bid for the entire insulin collection line, hoping for an opportunity to increase share
Commonwealth Pharmaceuticals (3933.HK): Excellent intermediate/API performance, rich GLP-1 pipeline
Federal Pharmaceuticals (3933.HK): High growth in the pharmaceutical intermediate drug Gaojing pneumatic protection business continues
Federal Pharmaceuticals (3933.HK): Profit in 2023 exceeds expectations and will grow steadily in the future
CICC: Maintaining Federal Pharmaceuticals' (03933) “Outperform the Industry” rating target price increase by 31% to HK$10.5
Federal Pharmaceuticals (03933.HK): 2023 profit exceeds expectations 6-APA price is high and strong
Bank Rating|China-Thailand International: Raising the federal pharmaceutical rating to “increase holdings” and slightly raised the target price to HK$9.7
China-Thailand International: Adjusting the rating of Federal Pharmaceuticals (03933) to “increase holdings” and slightly raised the target price to HK$9.7
Federal Pharmaceuticals (3933 HK): Expected to perform well in 2023
Bank Ratings | Goldman Sachs: Raising the target price of federal pharmaceuticals to HK$8.81 and raising the rating to “neutral”
Federal Pharmaceuticals (03933.HK): High profit growth, strong demand for intermediates and APIs
Federal Pharmaceuticals (3933.HK): The volume and price of API intermediates have risen sharply to meet the inflection point of insulin
Federal Pharmaceuticals (03933.HK): 1H23 performance exceeded expectations, rapid growth in intermediates and APIs
Federal Pharmaceuticals (3933.HK): Intermediates and APIs Will Lead High Performance Growth in 2023
Federal Pharmaceuticals (3933.HK): A recovery in overseas demand drives a high rise in API and waits for the inflection point of insulin
Federal Pharmaceuticals (3933.HK): Achieving rapid growth in performance and accelerated development of new drugs
Federal Pharmaceuticals (3933.HK): The API business performed brilliantly, and the insulin business came out of the haze of collection
Federal Pharmaceuticals (03933.HK): API and animal insurance revenue grew rapidly, net profit exceeded expectations
Federal Pharmaceuticals (03933.HK) 2022 Annual Report Review: Intermediates and API Prices Rise, Performance Growth Exceeds Expectations
No Data